Oncology

Spain-based Endometrial Cancer Diagnostics Company MiMark Receives €1.5M Investment from EIT Health

Barcelona-based company MiMARK has received €1.5M in funding from EIT Health following the EIT Health Wild Card program. The company is working on improving accuracy and efficiency of diagnostics for endometrial cancer. Abnormal vaginal bleeding affects 9M women in EU and US yearly. Diagnosis of endometrial cancer is mandatory since 10% of these women will suffer it. Current diagnosis is based on the pathological…

Women’s Health Biotech Company Aspira Plans to Raise $45M with Its Recently Announced Public Offering of Common Stock

Aspira, a bio-analytical based women’s health company focused on gynecologic disease, has announced plans to raise $45 million through a public offering of common stock. The company intends to use the net proceeds from the offering for sales and marketing, working capital and other general corporate purposes, including investing in additional key strategic hires, product portfolio expansion and research and development. Aspira…

Veteran Biotech Executive Elizabeth Cormier-May Joins Women’s Health Startup Mammogen as the Company’s New CEO

Mammogen, a women’s health startup born at the intersection of data, technology and science has announced the appointment of Elizabeth Cormier-May as Chief Executive Officer and member of the board of directors of Mammogen. She will begin her new role on March 1st, 2021.   In her new role, Cormier-May will lead efforts to develop, validate and commercialize the company’s flagship liquid biopsy program for…

Hologic and Google Cloud Announce Collaboration to Advance Next Generation Digital Diagnostic Capabilities in Cervical Cancer Screening

Hologic announced today a multi-year strategic collaboration with Google Cloud that will feature the integration of Google Cloud’s machine learning (ML) technologies with Hologic’s cutting-edge Genius Digital Diagnostics System to transform screening and accelerate the eradication of cervical cancer across the globe. Genius Digital Diagnostics is the first digital cytology platform to combine artificial intelligence (AI) with advanced digital imaging to help identify pre-cancerous…

Femtech Company MobileODT is Awarded a $2.3M Grant from the National Cancer Institute

MobileODT, a femtech company innovating in cervical screening, has been awarded a prestigious Small Business Innovation Research Authority grant of $2.3 million. This grant is presented by the United States National Cancer Institute (NCI) to leading companies that are technologically and clinically advanced to support the NCI’s goal of reducing suffering and death due to cancer. This grant is a tribute to the…

SynDexRx: New Drug Tackles the Relationship Between Obesity and Breast Cancer

While cancer therapies are getting more personalized (and expensive), patient outcomes don’t seem to improve along the same trajectory and SynDevRx believes to know why that is. According to the company’s research the answer lies in the way that obesity, diabetes, and other forms of metabolic dysfunction accelerate tumor growth and metastasis, making at least 13 common types of cancer much more…

Pregna Launches CryoPop, a Carbon Dioxide (CO2) Based Innovative Cryotherapy Device to Fight Cervical Cancer

Pregna has recently announced the launch of its cryotherapy device CryoPop. The product was developed by Jhpiego with an objective of making treatment of cervical pre-cancerous lesions accessible to all. Pregna is the exclusive global commercialising partner for the device. “Cervical cancer is one of the most common and fatal forms of cancer in women worldwide, with about 85% of these deaths occurring in low and…

BioAesthetics Announces a $5M Series A to Commercialize NACgraft, a Regenerative Nipple Graft for Breast Cancer Survivors

BioAesthetics Corporation today announced that it has doubled its initial Series A funding goal of $2.5 million, closed on Dec. 30, 2020, at $5 million to commercialize its NACgraft biologic matrix— a regenerative nipple graft for breast cancer survivors. BioAesthetics’ Series A was co-led by FemHealth Ventures and personally by BioAesthetics’ Director Sandra Coufal, MD, of Sibling Capital Ventures. BioAesthetics’ inaugural product, the NACgraft — for patients…